Fbxo3-Dependent Fbxl2 Ubiquitination Mediates Neuropathic Allodynia through the TRAF2/TNIK/GluR1 Cascade
Open Access
- 16 December 2015
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 35 (50) , 16545-16560
Abstract
Emerging evidence has indicated that the pathogenesis of neuropathic pain is mediated by spinal neural plasticity in the dorsal horn, which provides insight for analgesic therapy. Here, we report that the abundance of tumor necrosis factor receptor-associated factor 2 and NcK-interacting kinase (TNIK), a kinase that is presumed to regulate neural plasticity, was specifically enhanced in ipsilateral dorsal horn neurons after spinal nerve ligation (SNL; left L5 and L6). Spinal TNIK-associated allodynia is mediated by downstream TNIK–GluR1 coupling and the subsequent phosphorylation-dependent trafficking of GluR1 toward the plasma membrane in dorsal horn neurons. Tumor necrosis factor receptor-associated factor 2 (TRAF2), which is regulated by spinal F-box protein 3 (Fbxo3)-dependent F-box and leucine-rich repeat protein 2 (Fbxl2) ubiquitination, contributes to SNL-induced allodynia by modifying TNIK/GluR1 phosphorylation-associated GluR1 trafficking. Although exhibiting no effect on Fbxo3/Fbxl2/TRAF2 signaling, focal knockdown of spinal TNIK expression prevented SNL-induced allodynia by attenuating TNIK/GluR1 phosphorylation-dependent subcellular GluR1 redistribution. In contrast, intrathecal administration of BC-1215 (N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]-1,2-ethanediamine) (a novel Fbxo3 inhibitor) prevented SNL-induced Fbxl2 ubiquitination and subsequent TFAF2 de-ubiquitination to ameliorate behavioral allodynia via antagonizing TRAF2/TNIK/GluR1 signaling. By targeting spinal Fbxo3-dependent Fbxl2 ubiquitination and the subsequent TRAF2/TNIK/GluR1 cascade, spinal application of a TNF-α-neutralizing antibody ameliorated SNL-induced allodynia, and, conversely, intrathecal TNF-α injection into naive rats induced allodynia via a spinal Fbxo3/Fbxl2-dependent modification of the TRAF2/TNIK/GluR1 cascade. Together, our results suggest that spinal TNF-α contributes to the development of neuropathic pain by upregulating TRAF2/TNIK/GluR1 signaling via Fbxo3-dependent Fbxl2 ubiquitination and degradation. Thus, we propose a potential medical treatment strategy for neuropathic pain by targeting the F-box protein or TNIK.SIGNIFICANCE STATEMENTTNF-α participates in neuropathic pain development by facilitating the spinal TRAF2-dependent TNIK–GluR1 association, which drives GluR1-containing AMPA receptor trafficking toward the plasma membrane. In addition, F-box protein 3 modifies this pathway by inhibiting F-box and leucine-rich repeat protein 2-mediated TRAF2 ubiquitination, suggesting that protein ubiquitination contributes crucially to the development of neuropathic pain. These results provide a novel therapeutic strategy for pain relief.Keywords
This publication has 40 references indexed in Scilit:
- A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammationNature Immunology, 2013
- AMPA receptor trafficking in inflammation-induced dorsal horn central sensitizationNeuroscience Bulletin, 2012
- Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injuryEuropean journal of pain, 2011
- Increased Expression of Sodium Channel Subunit Nav1.1 in the Injured Dorsal Root Ganglion After Peripheral Nerve InjuryThe Anatomical Record, 2011
- Knockdown of mental disorder susceptibility genes disrupts neuronal network physiology in vitroMolecular and Cellular Neuroscience, 2011
- The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and functionMolecular Psychiatry, 2010
- Peripheral inflammation induces tumor necrosis factor dependent AMPA receptor trafficking and Akt phosphorylation in spinal cord in addition to pain behaviorPain, 2010
- SCRAPPER-Dependent Ubiquitination of Active Zone Protein RIM1 Regulates Synaptic Vesicle ReleaseCell, 2007
- UBE3A/E6-AP mutations cause Angelman syndromeNature Genetics, 1997
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983